Ratings UroGen Pharma Ltd.

Equities

URGN

IL0011407140

Real-time Estimate Cboe BZX Other stock markets 02:52:36 2024-04-23 pm EDT			5-day change	1st Jan Change
14.72 ^USD	+2.44%		+2.14%	-1.33%

Apr. 15	UroGen Pharma Says FDA Accepts Investigational New Drug Application for Potential Bladder Cancer Treatment	MT
Apr. 03	UroGen Pharma Sues Teva Pharmaceuticals Over Alleged Patent Infringement of Jelmyto	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
UROGEN PHARMA LTD.	-1.33%	490M	B-
VERTEX PHARMACEUTICALS INCORPORATED	-0.41%	103B	B+
REGENERON PHARMACEUTICALS, INC.	+3.60%	96.73B	B+
ARGENX SE	+1.66%	21.31B	B
BIONTECH SE	-16.24%	21.21B	B+
GENMAB A/S	-6.82%	18.79B	A-
WUXI APPTEC CO., LTD.	-41.41%	16.37B	A-
BEIGENE, LTD.	-23.18%	13.68B	B
NEUROCRINE BIOSCIENCES, INC.	+6.88%	13.44B	C+
SAREPTA THERAPEUTICS, INC.	+22.88%	10.98B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes